Sareum Holdings (SAR)

 

Latest News

Placing

RNS Number: 4679W Sareum Holdings PLC 14 November 2017 (AIM: SAR) 14 November 2017 Sareum Holdings plc ("Sareum" or "the Company") Placing Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, announces that it has raised 700,000, before expenses, through a placement via Hybridan LLP as agent of the Comp...

Sareum notes experiment progress

Sareum Holdings has noted that Sierra Oncology, the licence holder advancing a clinical cancer candidate Chk1 inhibitor, r...

Sierra Reports Preclinical Data for Chk1 Inhibitor

RNS Number: 0638V Sareum Holdings PLC 31 October 2017 (AIM: SAR) 31 October 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy - SRA737 demonstrates synergy with replication stress-inducing agents - - SRA737 plus gemci...

Sareum reports maiden profit of £400,000

Sareum, a cancer drug discovery and development company, made a maiden profit after tax on ordinary activities of 400...

All News

DateHeadlineSource
14-11-17PlacingRNS
31-10-17Sareum notes experiment progressStockMarketWire
31-10-17Sierra Reports Preclinical Data for Chk1 InhibitorRNS
19-10-17Sareum reports maiden profit of £400,000StockMarketWire
19-10-17Final ResultsRNS
09-10-17Sierra Oncology host KOL Meeting on 12 Oct in NYRNS
18-09-17Sierra Oncology to host call on Chk1 inhibitorRNS
22-08-17Sareum profit after tax anticipated to beat expectationsStockMarketWire
22-08-17Pre-Close Trading StatementRNS
19-06-17Sareum to Present at the ICCS 2017RNS
05-06-17Sareum updates on Chk1 inhibitor trialsStockMarketWire
05-06-17Chk1 Clinical Trials UpdateRNS
31-05-17Sareum Holdings notes Sierra Oncology patentsStockMarketWire
31-05-17Sierra Oncology Granted US and EU PatentsRNS
25-05-17Sierra Oncology to Present at ASCO Annual MeetingRNS
09-05-17Sareum to Present at BioTrinity 2017RNS
09-03-17Director Deals - Sareum Holdings PLC (SAR)StockMarketWire
09-03-17Director ShareholdingRNS
20-02-17Sareum swings to H1 pretax profitStockMarketWire
20-02-17Half-year ResultsRNS
09-02-17Notice of Interim ResultsRNS
09-01-17Milestone Payment from Chk1 Licence AgreementRNS
22-12-16Result of General MeetingRNS
15-12-16Result of AGMRNS
06-12-16Directors' Remuneration & General MeetingRNS
29-11-16Sareum to Present at AACR-NCI-EORTC ConferenceRNS
21-11-16Notice of AGMRNS
02-11-16Sareum Holdings narrows FY pretax lossStockMarketWire
02-11-16Final ResultsRNS
24-10-16Sareum says TYK2 feasibility study successfulStockMarketWire
24-10-16Successful Outcome from TYK2 Feasibility StudyRNS
17-10-16Sareum notes Japan, Singapore Patent GrantsStockMarketWire
17-10-16Japan and Singapore Patent GrantsRNS
27-09-16Banks keep FTSE in the red StockMarketWire
27-09-16Licence agreement for Chk1 Inhibitor CCT245737RNS
03-08-16Sareum confirms patent grants for Aurora+FLT3StockMarketWire
03-08-16China & HK Patent Grants for Sareum's Aurora+FLT3RNS
28-07-16Sareum comments on share-price moveStockMarketWire
28-07-16Movement in share priceRNS
23-05-16Clinical Trials CHK1 Inhibitor CCT245737 to OpenRNS

RSS feeds

  • Editorial news feed for LSE:SAR Editorial
  • Regulatory news feed for LSE:SAR Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account